BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn (PRNewswire) - Jun 17, 2025 - P=NA | N=10 | NCT04681118 | Sponsor: Brainstorm-Cell Therapeutics | "BrainStorm Cell Therapeutics Inc...today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial....90% of participants (9/10) survived more than five years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS survive beyond five years. Notably, the single death in the cohort occurred following elective euthanasia. The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset."
Clinical data • Amyotrophic Lateral Sclerosis
|